ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) said its Dutch subsidiary U-Protein Express BV has taken a long term lease at the new multi-tenant facility at the Utrecht Science Park, which will encourage collaborations in the life sciences space.
The building's design is the vision of listed biotechs Genmab (NASDAQ:GMAB) and Merus NV (NASDAQ:MRUS) and is said to create a unique hub within the 'innovation ecosystem'.
"We are delighted to move our continuously expanding service activities towards the new building alongside important stakeholders such as Genmab and Merus," said Dr Martin Hessing, General Manager of U-Protein Express.
"This will enable us to keep in pace with our growing contract research business as Accelerator will give us over 3-4 times current capacity."
Dr Jennifer Bath, President and CEO of Victoria, British Columbia-based ImmunoPrecise Antibodies, said: "The investments we are making in our European operations are a strong reflection of ImunoPrecise's position in the marketplace and positive outlook for the future.
"The Accelerator provides state-of-the-art facilities that enable our talented team to respond to the increasing demand for our services and innovative technologies."
Contact the author at [email protected]